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In children and adolescents small size of the hip bones and ana-
tomic changes due to underlying disease may make total hip 
arthroplasty (THA) technically demanding, and in the young-
est high activity level is a risk factor for revision (Munger et al. 
2006, Flugsrud et al. 2007, Prokopetz et al. 2012). It is reason-
able to expect revision surgery throughout the patient’s lifes-
pan. In all ages the reduced bone stock after revision surgery 
may cause later problems, the implant survival may be poor 
and recovery of function is more strenuous (Lie et al. 2004, 
Bischel et al. 2012, Adelani et al. 2014, Goodman et al. 2014). 
Reports decades ago on THAs in patients younger than 21 
years were mostly on patients with juvenile chronic arthropa-
thies and most of the components were cemented (Ruddlesdin 
et al. 1986, Witt et al. 1991, Cage et al. 1992). Historically, 
long-time cohorts of cemented THAs demonstrate down to 
50% implant survival after 12–19 years (Torchia et al. 1996, 
Wroblewski et al. 2010). Later studies have found more 
promising results with uncemented implants. Hannouche et 
al. (2016) found an estimated 90% survival after 10 years 
in patients aged less than 20 years with almost exclusively 
uncemented implants with ceramic-on-ceramic bearings. Tsu-
kanaka et al. (2016) found a 10-year survival rate of 70% in 
a Norwegian register study of 96 cemented and uncemented 
hips in 81 patients aged less than 20 years. A recent register 
study of 769 THAs in patients 20 years or younger from Eng-
land, Wales, Northern Ireland, and the Isle of Man reported a 
5-year implant survival of 96%. The patients included were 
from the period 2003–2017 (Metcalfe et al. 2018).
Background and purpose — The literature is scarce on 
the outcome of the youngest patients with total hip arthro-
plasties (THAs). We analyzed register data, revision risk, and 
related factors in patients 21 years or younger with THAs in 
the Nordic Arthroplasty Register Association (NARA).
Patients and methods — We included all THA patients 
21 years or younger reported during 1995 through 2016 to 
the Danish, Finnish, Norwegian, and Swedish hip arthro-
plasty registers and merged these into the NARA dataset. 
Primary outcome was any implant revision.
Results — We identified 881 THAs in 747 patients. Mean 
age at primary surgery was 18 years (9–21). The indications 
for THA were pediatric hip diseases (33%), systemic inflam-
matory disease (23%), osteoarthritis (4%), avascular necro-
sis (12%), hip fracture sequelae (7%), and other diagnoses 
(21%). Unadjusted 10-year survival for all THAs was 86%. 
Comparison between indications showed no differences in 
survival. Uncemented implants were used most frequently. 
Survival for uncemented and cemented implants was the 
same adjusted for sex, indication, head size, and time period 
for primary surgery. Aseptic loosening was the main cause 
of revision.
Interpretation — Both cemented and uncemented fixa-
tions seem to be a viable option in this age group, but with a 
lower implant survival than in older patient groups.
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all covariates. We used log–log plots and Schoenfeld residu-
als for each covariate to test that the Cox proportional hazard 
model was fulfilled. Bilateral observations do not introduce 
significant dependency problems in register studies, hence 
these were included (Ranstam et al. 2011).
Ethics, funding, and potential conflict of interest 
Ethical approval: Denmark: Danish Data Protection Agency 
nr. 1-16-02-54-17, Finland: National Institute of Helath and 
Welfare (THL): Dnro THL/1743/5.05.00/2014, Norway: 
Norwegian Data Protection Authority 03/00058-20/CGN, 
Sweden: DNR 804-17 Regional ethical committee Gothen-
burg. Research was funded by NordForsk Grant for NARA.
No conflict of interest was reported by the authors.
Results
Demographic data and diagnosis
The number of primary THAs in patients 21 years or younger 
was 881 (0.1%) compared with 745,827 primary THAs in 
patients of all ages during the 22-year study period. Of the 
881 THAs, 134 were bilateral procedures (18%). 43% of the 
bilateral cases were performed in systemic inflammatory dis-
ease patients (SID patients). 
The male:female ratio was close to 1:1, except in Sweden 
where the ratio was almost 1:2. Mean age at primary THA 
was 18 (9–21) years (SD 2.4). Mean age at primary surgery 
was similar for males and females. Pediatric hip disease was 
the most common indication for THA accounting for 33% 
of the patients; the second largest group was SID with 23%, 
OA accounted for 4%, AVN for 12%, hip fractures for 7%, 
and other for 21%. The indications for THA varied during the 
We present an epidemiologic overview on more recent 
primary THAs regarding indications and fixation concepts. 
Implant survivorship and reasons for revision were evaluated. 
Patients operated in the first years of the study period may 
have limited applicability to contemporary THAs because of 
older implant design. Our hypothesis was that newer implants 
might have better survival compared with those used in the 
earlier cohort. 
Patients and methods
Data source
This study was based on data from the Nordic Arthroplasty 
Register Association (NARA), which is a collaboration 
between the national joint replacement registers in Denmark, 
Finland, Norway, and Sweden (Mäkelä et al. 2014). Data from 
the registers have been merged into a common NARA mini-
mal dataset combining available parameters in all four coun-
tries. The study is reported according to RECORD guidelines.
Study population
Using the NARA database, we identified all patients 21 years 
or younger (n = 747) reported to have had 881 primary THAs 
during 1995–2016. 
Covariates
Information on country of origin, age, sex, indication for 
THA, calendar year of surgery, type of fixation, implants and 
articulations, approach, cause of any revision, and date of 
death were collected. No THAs were excluded even if there 
were missing values in some categories in the dataset. The 
diagnoses for primary THA were grouped into 6 categories 
(Figure 1). 
Outcome
The primary outcome measure was time to 1st revision. A 
revision was defined as any removal or exchange of compo-
nents. Revisions were categorized as change of cup, change of 
stem, change of both stem and cup, or removal of components. 
In the NARA minimal dataset changing of liner is recorded as 
cup revision. Only the 1st revision was reported.
Statistics
Categorical data were cross-tabulated by the chi-square test. 
Continuous data were described using means (SD), and pos-
sible differences were tested with Student’s t-test. All tests 
were 2-sided and the significance level was set to 0.05. The 
Kaplan–Meier method was used to calculate unadjusted sur-
vival functions and estimates with 95% confidence interval 
(CI). In order to examine the association between sex, diag-
nosis, type of fixation, femoral head size, calendar period, and 
risk of revision, we calculated the hazard ratio (HR) using Cox 
regression analyses, crude HR, and HR mutually adjusted for 
Figure 1. Indications for THAs in patients 21 years or younger in NARA 
countries 1995–2016. Other: tumors, sequelae after infection, pharma-
ceutically induced femoral necrosis. Pediatric: developmental dysplasia 
of the hip (DDH), Perthes, slipped capital femoral epiphysis (SCFE). 
SIDs: systemic inflammatory diseases including rheumatoid arthritis, 
ankylosing spondylitis, and other inflammatory diseases. AVN: avascu-
lar necrosis. OA: osteoarthritis.
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study period; there was a trend towards declining frequency 
of SID and increasing frequency of pediatric diseases (Figure 
1, Table 1). There were differences among the Nordic coun-
tries between indications, particularly the pediatric and SID 
groups, which varied from 11% to 51% and 17% to 35% 
respectively (Table 1). 
Fixations, head size, articulations, 
implants, and surgical approach
In total, 74% of the implants were uncemented 
(Table 2). Hip resurfacing arthroplasty was 
rare (3.6%). We found no obvious association 
between diagnosis and type of fixation, which 
was equally distributed among different diag-
noses. 25% of the heads were 32 mm and 46% 
were smaller. Metal on highly crosslinked 
polyethylene was the most frequent articula-
tion (18%). Type of articulation was missing in 
19% of cases. A posterior approach was used 
in 47% of the operations (Table 2). 
Implant brands
The number of different brands varied from 9 
to 22 for cups and 10 to 21 for stems for each 
of the participating countries. The variety of 
brands was similar in the latter period (2012–
2016) compared with the first two (1995–2004 
and 2005–2011). Implant survival estimates 
linked to brands cannot be performed due to 
the heterogenicity of the material and the rela-
tively small number of THAs. 
Implant survival and revisions
118 (13%) of the 881 THAs were revised 
during the study period (Table 1). With any 
reason for revision as endpoint, the 5-year 
unadjusted survival was 94% (CI 92–96), the 
10-year survival was 86% (CI 83–89), and the 
15-year survival 73% (CI 68–78) (Figure 2). 
Cups had a higher revision rate than stems 
(Figure 3). There were 4 types of fixations: 
cemented, uncemented, hybrid (cup unce-
mented, stem cemented), and reverse hybrid 
(cup cemented, stem uncemented) and in 
addition 31 resurfacing arthroplasties (3.6%). 
Table 1. Patient demographics for each country with a total of 881 primary THAs in 
1995–2016 (numbers in parentheses)
Country  Denmark   Finland   Norway   Sweden    Total
THAs per country, n (%) 253 (29) 171 (19) 207 (24) 250 (28)  881
Revisions, n (%)   28 (11)   30 (18)   17 (8)   43 (17)  118 (13)
Number of deaths     6 2 7 8 23
Sex, % male   53 52 50 36 47
Age, mean (SD) 17.9 (2.3) 18.3 (2.4) 17.8 (2.4) 18.1 (2.4)  18.0 (2.4)
Indications, %
 Osteoarthritis 2.4 8.8 1.4 4.8    4.1
  Avascular necrosis 11 15 11 12    12
 Hip fracture 5.6 7.6 5.3 7.6    6.5
  SID a 18 21 17 35    23
  Pediatric  48 11 51 18    33
  Other 15 36 15 23    22
In 1.2% of the operations information on indication was missing.
a Systemic inflammatory disease.
Table 2. Fixations, head sizes, articula-
tions, surgical approach, and trochan-
teric osteotomies (n = 881). Values are 
frequency (%)
Fixations
 Cemented 62 (7.0)
 Uncemented 659 (74)
 Hybrid 36 (4.1)
 Reverse hybrid 78 (8.9)
 Resurfacing 31 (3.5)
 Missing 15 (1.7)
Head size 
 < 32 mm 405 (46)
 32 mm 221 (25)
 > 32 mm 180 (20)
 Missing 75 (8.5)
Articulation 
 Metal/metal 145 (17)
 Metal/ceramic    1 (0.1)
 Ceramic/ceramic 97 (11)
 PolyXL/metal    206 (23)
 PolyXL/ceramic 135 (15)
 Poly/metal 78 (8.9)
 Poly/ceramic 54 (6.1)
 Missing 165 (19)
Posterior approach a
 Yes 418 (47)
 No 262 (30)
 Missing 201 (23) 
Trochanteric osteotomy  
 Yes 21 (2.4)
 No 658 (75) 
 Missing a 202 (23)
a Finland did not report approach. 
Table 3. Causes of revisions and revision 
procedures performed (n = 118). Values 
are frequency (%)
Cause  
 Aseptic loosening 61 (52)
 Deep infection 6 (5.1)
 Periprosthetic fracture 3 (2.5)
  Dislocation 11 (9.3)
 Pain only 1 (0.8)
  Other 36 (31)
Procedure a 
 Total replaced 11 (9.3)
 Only stem replaced 6 (5.1)
 Only cup or liner replaced 39 (33)
 Girdlestone 3 (2.5)
 Other 29 (25)
  Missing 30 (25)
a Finland did not report procedure. Den-
mark did not differ between cup, stem, 
or total revision and data are reported as 
“other.”
Adjusted data showed no statistically significant survival dif-
ference between cemented and uncemented implants (p = 0.2, 
Table 4).
The numbers per disease were too small to make meaning-
ful estimates of survivorship related to disease.
Hazard ratio (HR) for revision was analyzed in different time 
periods (Table 4). Unadjusted HR was 0.5 (CI 0.3–0.8) for the 
years 2005–2011 and 0.4 (CI 0.1–1.0) for 2012–2016 com-
pared with 1995–2004. Adjusted for sex, indication, fixation, 
and head size the HR in the period 2005–2011 was 0.5 (CI 0.3–
0.9) and 0.6 (CI 0.2–1.8) in the period 2012–2016 compared 
with 1995–2004. In 2012–2016 only 5 revisions were recorded. 
Using the period 1995–2011 as HR reference, HR in the period 
2012–2016 was 0.5 (CI 0.2–1.3) (data not shown in table). The 
hazard ratio for revision was 2.5 (95% CI 1.4–4.5) higher for 
reverse hybrid than for uncemented fixation (Table 4). 
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Table 4. Patient- and procedure-related risk factors for THA revision in patients 21 
years and younger at surgery adjusted for sex, indications, head size, implant fixation, 
and time period (n = 881)
 Total No. of Unadjusted  Adjusted 
Variables number revisions HR (95% CI) p-value HR (95%CI) p-value
Sex      
  Men 418 46 1  1 
  Women 463 72 1.1 (0.8–1.6)  0.6 1.1 (0.7–1.7) 0.8
Indication (n = 879):      
  Pediatric 290 30 1  1 
  Osteoarthritis 36 1 0.2 (0.1–1.7) 0.2 – 
  Avascular necrosis 104 7 0.6 (0.2–1.3) 0.2 0.5 (0.2–1.3) 0.2
  Hip fracture 57 6 1.2 (0.5–2.8) 0.7 1.5 (0.5–3.9) 0.5
  SIDs 203 52 1.2 (0.8–1.9) 0.4 0.9 (0.5–1.7) 0.9
  Other 189 22 1.0 (0.5–1.7) 0.9 1.1 (0.6–2.1) 0.7
Fixation (n = 866):      
  Uncemented 659 69 1  1 
  Cemented 62 20 1.9 (1.2–3.2) 0.01 1.6 (0.8–3.2) 0.2
  Hybrid 36 5 0.7 (0.3–1.8) 0.5 0.5 (0.2–1.8) 0.3
  Reverse hybrid  78 17 2.4 (1.4–4.0) 0.002 2.5 (1.4–4.5) 0.002
  Resurfacing 31 7 1.8 (0.8–4.0) 0.1 0.9 (0.2–4.7) 0.9
Head size (n = 806):      
  < 32 mm 405 76 1  1 
   32 mm 221   4 0.3 (0.1–0.8) 0.01 0.4 (0.1–1.3) 0.1
  > 32 mm 180 8 0.4 (0.2–0.8) 0.02 0.7 (0.3–1.9) 0.5
Time period:      
  1995–2004 274 90 1  1 
  2005–2011 311 23 0.5 (0.3–0.8) 0.007 0.5 (0.3–0.9) 0.02
  2012–2016 296 5 0.4 (0.1–1.0) 0.05 0.6 (0.2–1.8) 0.4
Figure 2. Kaplan–Meier revisionfree survival 
curve. Confidence intervals are shaded. The 
10-year survival was 86%.
Figure 3. Kaplan–Meier survival curves for 
cups (red) and stems (blue). Confidence inter-
val are shaded. Data from Finland are not 
included because surgical procedure at revi-
sion is not registered. 
Figure 4. Kaplan–Meier unadjusted survival 
curves with confidence intervals (shaded 
areas) for different fixation methods with unce-
mented fixation as reference. (a) Uncemented 
versus cemented; (b) uncemented versus 
hybrid; (c) uncemented versus reverse hybrid. 
For adjusted survival see Table 4. 31 resurfac-
ing arthroplasties were not included. 
a
b
c
Patients at risk in Figures 2–4
Years from surgery:  0 2 4 6 8 10 12 14 16 18 20
 
Figure 2:  881 738 597 474 357 272 196 132 99 60 27
Figure 3:   710 584 462 361 269 201 145 101 72 43 19
Figure 4: Uncemented 659 540 422 330 243 185 127 85 70 45 24
   Cemented  62 56 50 45 40 36 28 19 11 3 1
   Hybrid  36 30 28 25 22 20 19 16 10 6 1
   Reverse hybrid  78 71 63 45 29 14 9 6 4 2 0
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There were no revisions recorded where removal of com-
ponents took place. That would probably have been the case 
if more than the first revision had been reported. Most of the 
revisions, 52%, were due to aseptic loosening (Table 3). 
Discussion
The overall 10-year implant survival was 86%. There was no 
difference in adjusted survival for cemented and uncemented 
implants. Reverse hybrid fixation had a higher hazard ratio for 
revision than other fixations. We could not show a convincing 
trend towards better survivorship in the latter time period. 
One-third of the patients had pediatric hip disease. The 
increase in the number of pediatric hip disease indications 
cannot be explained by changes in DDH screening since the 
screening programs have been unchanged over the years. 
Neither have any changes in the incidences of Perthes disease 
or slipped capital femoral epiphysis been reported in the lit-
erature. There are also differences between the countries con-
cerning pediatric hip disease as indication, but a study of hip 
radiograms at skeletal maturity showed that the prevalence 
of developmental dysplasia of the hip is on the same level 
in the Nordic countries (Engesaeter et al. 2013). Moreover, 
Lohmander et al. (2006) has found for all ages that there were 
similar THA indications in the Nordic countries. A more 
stringent diagnostic approach might have taken place in some 
countries and over the years, explaining the development in 
this indication.
Systematic inflammatory disease as indication has declined 
over the years. The decline in SID as indication for sur-
gery was expected since powerful disease-modifying drugs 
(DMDs) have been on the market for more than 20 years. The 
decline in THA patients with SID might even continue during 
the next decade. 
The differences in SID as indication between the different 
countries may be reflecting that the incidence and prevalence 
of inflammatory arthropathies have been varying in different 
reports. Berntson et al. (2003) found an incidence of juvenile 
arthritis in the Nordic countries varying between 5/100,000 
and 36/100,000 in different areas. 
In accordance with Metcalfe et al. (2018), we did not find 
associations between indications for THA and implant sur-
vival. Hannouche et al. (2016) also found the same when 
he studied 91 patients, 113 hips, in patients younger than 20 
years with THAs with ceramic-on-ceramic bearings. Sev-
eral authors have found inferior implant survival in SIDs 
patients, especially in older series (Roach et al. 1984, Chmell 
et al. 1997, McCullough et al. 2006). One could expect SID 
patients to be less physically active than other young people 
and thus that the prosthesis would last longer. On the other 
hand, using DMDs may have helped patients to be physically 
more active over the years, hence increasing the risk of wear. 
We assume that our data on the youngest SID patients showed 
better survival because DMDs have had a favorable effect on 
morphological changes in the joint before surgery took place, 
therefore making the surgery less demanding. NARA data for 
THA patients in all ages have previously shown low revision 
rates in patients with pediatric hip disease. Engesaeter et al. 
(2012) found a 10-year survival of 94% after pediatric hip dis-
ease treated by THA for all ages. We could not find such a 
favorable trend for pediatric hip disease patients, which may 
be explained by different ages in the populations.
Unadjusted 5-year implant survival was 94% in our mate-
rial; 10-year survival was 86% and 15-year survival 73%. 
This is a 5-year implant survival comparable to the 96% sur-
vival in the recent national register study by Metcalfe et al. 
(2018). Our result is also comparable to a recent publication 
from the University of Utah with 145 THAs in patients 30 
years and younger included from 2000 to 2015 with a 10-year 
implant survival of 89% (Makarewich et al. 2018). Our 
implant survival is considerably better than results reported 
in a Norwegian study with surgery performed 1987–2010, 
which had a 10-year survival of 70% with endpoint any revi-
sion (Tsukanaka et al. 2016). The difference in survival might 
be explained by our more recent study period (1995–2016), 
which did not include inferior implants and bearing surfaces 
from the 1980s (Havelin et al. 2002).
During recent years there has been a trend in the literature 
towards using uncemented implants, which are thought to per-
form better in younger patients, but there are diverging results. 
In a systematic review Gee et al. (2013) found that among 450 
primary THAs in patients aged less than 30 years uncemented 
stems did better than cemented. Schmitz et al. (2013), con-
versely, found a 10-year survival of 86% with 69 cemented 
THAs in patients younger than 30 years in a Dutch study. Wro-
blewski et al. (2010) reported a 65% implant survival at 19 
years in 39 hips with cemented Charnley arthroplasties. Mean 
age at surgery was 18 years in his study. Data from the Aus-
tralian Orthopaedic Association National Joint Replacement 
Registry collected from September 1999 through December 
2012 of 297 THAs in patients younger than 21 years unveiled 
a 5-year revision rate of 4.5%. Many of the implants were 
resurfacings (Sedrakyan et al. 2014). We found that cemented 
and uncemented implants had similar survivorship (Table 4). 
Hybrid fixation had an adjusted HR of revision of 2.5 but, 
due to the relatively small numbers of THAs in each fixation 
group, the confidence intervals are wide and tend to overlap. 
Larger numbers would have given us more precise estimates 
and hence a clearer picture of survivorship for the different 
fixations (Figure 4). 
We found similar adjusted HRs for revision between the 3 
time periods analyzed (Table 4) and for the period 2012–2016 
compared with 1995–2011 (data not shown). The lack of a 
favorable trend over time might be due to the fact that in 2015 
there were only 27 hips at risk (Figure 2) and only 5 revisions 
were recorded in the period 2012–2016.
The main cause of revision in our study was aseptic loosen-
ing, which is in accordance with reports from earlier studies 
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(Dudkiewicz et al. 2003, Pakos et al. 2014, Sedrakyan et al. 
2014, Hannouche et al. 2016). There were only 9.3% disloca-
tions as cause of revision, even though 46% of the patients 
were operated with head sizes smaller than 32 mm (Table 4) 
and 46% of them were combined with posterior approach. 
37% had head size smaller than 28 mm combined with a pos-
terior approach (data not shown in table). A speculation might 
be that younger patients have stronger muscles around the hip 
preventing dislocations to a greater extent than older patients. 
The number of deep infections was low, but is under-reported 
in registers. There might have been soft tissue debridements 
that were not reported. Older patients often have comorbidi-
ties that make them more frail and susceptible to infection. 
Although our dataset is the largest to date, it should be inter-
preted with caution. The NARA minimal dataset contained 
only information common to all the registers in Denmark, 
Finland, Norway, and Sweden. A weakness in the study is 
that data on articulations, head sizes, surgical approaches, and 
revision procedures were not recorded during the entire study 
period for all countries. Complementing and harmonizing the 
Nordic register data is an ongoing process.
All countries used many different acetabular and femo-
ral components. The combinations of components made the 
material as a whole highly heterogeneous. The wide diversity 
of component designs jeopardizes a more detailed analysis of 
cemented and cementless components. 
In summary, analyzing data from the NARA dataset on 881 
total hip replacements on patients 21 years or younger there 
was a decline in systemic inflammatory disease as indication 
for THA, and the overall survival at 10 years was 86% with 
reverse hybrid fixation showing less favorable survival. Sur-
vival for cemented and uncemented implants was the same 
adjusted for sex, indication, head size, and time period for 
index surgery.
All the authors made a substantial contribution to the conception of the 
study. AMF created the dataset with the NARA study group and conducted 
the statistical analyses. All the authors critically revised the draft prepared 
by VH.
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